ChemioCare Initiates Development Program in Pediatric CINV
January 04, 2019 17:52 ET
|
ChemioCare
NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult...
ChemioCare Expands Proprietary Transdermal Platform
October 18, 2018 20:11 ET
|
ChemioCare
DEA Registration granted: expands capability to develop controlled substances via transdermal patches NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the...
ChemioCare Announces Addition of Three Experienced Team Members
July 30, 2018 18:00 ET
|
ChemioCare
NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...
ChemioCare Announces Addition of Chief Medical Advisor and Director
May 01, 2018 10:00 ET
|
ChemioCare
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...
ChemioCare Formed to Transform Chemo-Induced Emesis Outcomes Through Patch Technology
March 06, 2018 10:00 ET
|
ChemioCare
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare”) today announced it will be leveraging novel transdermal patch technology for the treatment of chemotherapy-induced...